Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of various rhenium-188-labeled diphosphonates for the treatmentof bone metastases
Autore:
Hsieh, BT; Hsieh, JF; Tsai, SC; Lin, WY; Wang, SJ; Ting, G;
Indirizzi:
Taichung Vet Gen Hosp, Dept Nucl Med, Taichung 407, Taiwan Taichung Vet Gen Hosp Taichung Taiwan 407 Nucl Med, Taichung 407, Taiwan Inst Nucl Energy Res, Lungtan, Taiwan Inst Nucl Energy Res Lungtan Taiwan st Nucl Energy Res, Lungtan, Taiwan Chi Mei Fdn Hosp, Tainan, Taiwan Chi Mei Fdn Hosp Tainan TaiwanChi Mei Fdn Hosp, Tainan, Taiwan Show Chwan Mem Hosp, Dept Nucl Med, Changhua, Taiwan Show Chwan Mem Hosp Changhua Taiwan sp, Dept Nucl Med, Changhua, Taiwan
Titolo Testata:
NUCLEAR MEDICINE AND BIOLOGY
fascicolo: 8, volume: 26, anno: 1999,
pagine: 973 - 976
SICI:
0969-8051(199911)26:8<973:COVRDF>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
PAINFUL OSSEOUS METASTASES; RE-186 HYDROXYETHYLIDENE DIPHOSPHONATE; DOUBLE-BLIND CROSSOVER; PROSTATE-CANCER; METHYLENE DIPHOSPHONATE; GENERATOR; THERAPY; SR-89; RADIOPHARMACEUTICALS; BIODISTRIBUTION;
Keywords:
rhenium-188; diphosphonate; bone metastases; MDP; HDP; HEDP;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Lin, WY Taichung Vet Gen Hosp, Dept Nucl Med, 160 Taichung Harbor Rd,Sec 3, Taichung 407, Taiwan Taichung Vet Gen Hosp 160 Taichung Harbor Rd,Sec 3 Taichung Taiwan 407
Citazione:
B.T. Hsieh et al., "Comparison of various rhenium-188-labeled diphosphonates for the treatmentof bone metastases", NUCL MED BI, 26(8), 1999, pp. 973-976

Abstract

In the past, many diphosphonates were introduced as bone scan radiopharmaceuticals. In addition, diphosphonates have been labeled with beta-emitted isotopes and developed into useful therapeutic drugs for bone metastases. However, it is not clear which diphosphonate is the best choice when labelingwith Re-188. In this study, we labeled methylene diphosphonate (MDP), hydroxyethylidene diphosphonate (HEDP), and hydroxymethane diphosphonate (HDP) with Re-188. Each radiopharmaceutical was further evaluated in two conditions (with and without carrier). Twenty-four rabbits were used (four in each group) for the analysis of the biodistributions and bone uptakes of these radiopharmaceuticals to assess their potential for clinical applicability. Four hours after intravenous injection of approximately 37 MBq (1 mCi) Re-188-labeled diphosphonate preparations, whole body scans were performed usinga large-field gamma camera equipped with a high resolution collimator. Bone to-soft tissue ratios (B/S ratio) were calculated using a computer program. Our data showed that Re-188 HEDP with carrier (10(-4) M carrier) could accumulate in the skeletal system whereas very little absorption by bone wasobserved in the rabbits that were injected with carrier free Re-188 HEDP. In addition, no significant bone uptake was demonstrated for Re-188 MDP or Re-188 HDP, with or without carrier. The B/S ratio was 25.06 in the Re-188 HEDP with carrier group but less than 3 in the other groups. In conclusion,HEDP is the best choice among these three bone-seeking drugs when labeled with Re-188. But, it is necessary to add carrier when preparing Re-188 HEDPfor the treatment of bone metastases. (C) 2000 Elsevier Science Inc. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/09/20 alle ore 21:59:17